Companion Animal Drugs Market by Product Type (Antimicrobials, Ectoparasiticides, Endoparacitides, Endectoparaciticides, Anti-inflammatory Drugs, Anti-Obesity Drugs, Behavioral Products, Biologic Drugs and Others), By Animal Type (Feline, Canine, and Equine), By Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Veterinary Pharmacies, Veterinary Hospitals, Veterinary Clinics, and E-Commerce), and Geography.

   

Global Companion Animal Drugs Market is estimated to be valued US$ 12 Bn in 2021 and poised to grow at CAGR of 6.3% over 2022-2028 to reach USD 19.81 Bn by 2028 owing to rising human and companion animal by means of adoption across the globe. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the companion animal pharmaceutical market report includes animal demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policymakers, and veterinary healthcare service providers engaged in manufacturing and supply of companion animal drug products. Several respondents and pet owners revealed that pet expenditure is increasingly becoming an integral part of their monthly expenditure and companion animals are part of several families across the developed and developing economies. Moreover, rising interactions between pets and human beings prompting the caregivers and pet owners to adopt better healthcare services to the companion animals is projected to drive market revenue growth over the forecast period.